Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Xu Chao

Showing results (211-220 of 281) with videos related to

Pageof 29
Sort By:
Clinical Lung Cancer|October 12, 2015
Anaplastic Lymphoma Kinase Variants and the Percentage of ALK-Positive Tumor Cells and the Efficacy of Crizotinib in Advanced NSCLCYuan-Yuan Lei, Jin-Ji Yang, Xu-Chao Zhang, et al.
Translational Lung Cancer Research|November 14, 2025
Single-cell RNA profiling reveals an immunosuppressive microenvironment in <i>EGFR</i> double-mutant non-small cell lung cancerJiao Yang, Jun-Wei Su, Hong-Rui Li, et al.
Cancers|January 8, 2023
Longitudinal Plasma Proteomics-Derived Biomarkers Predict Response to MET Inhibitors for MET-Dysregulated NSCLCGuang-Ling Jie, Lun-Xi Peng, Mei-Mei Zheng, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 27, 2011
Relative abundance of EGFR mutations predicts benefit from gefitinib treatment for advanced non-small-cell lung cancerQing Zhou, Xu-Chao Zhang, Zhi-Hong Chen, et al.
European Journal of Cancer (Oxford, England : 1990)|April 21, 2021
Clinical outcomes of non-small cell lung cancer patients with leptomeningeal metastases after immune checkpoint inhibitor treatmentsMei-Mei Zheng, Hai-Yan Tu, Jin-Ji Yang, et al.
Experimental Hematology & Oncology|November 11, 2021
MET amplification identified by next-generation sequencing and its clinical relevance for MET inhibitorsLun-Xi Peng, Guang-Ling Jie, An-Na Li, et al.
Journal of Genetics and Genomics = Yi Chuan Xue Bao|November 12, 2015
Integrative Analyses of Lung Squamous Cell Carcinoma in Ten Chinese Patients with Transcriptome SequencingLu-Lu Yang, Xu-Chao Zhang, Shao-Kun Chuai, et al.
Cancer Immunology, Immunotherapy : CII|December 8, 2017
Characterization of PD-L1 expression in Chinese non-small cell lung cancer patients with PTEN expression as a means for tissue quality screeningXu-Chao Zhang, Xu Cao, Chun Sun, et al.
BMC Cancer|February 26, 2016
Distribution and prognosis of uncommon metastases from non-small cell lung cancerFei-Yu Niu, Qing Zhou, Jin-Ji Yang, et al.
Thoracic Cancer|April 19, 2022
Clinical outcomes of EGFR+/METamp+ vs. EGFR+/METamp- untreated patients with advanced non-small cell lung cancerKai-Cheng Peng, Jun-Wei Su, Zhi Xie, et al.
Pageof 29

Showing results (211-220 of 281) with videos related to

Sort By:
Pageof 29
Clinical Lung Cancer|October 12, 2015
Anaplastic Lymphoma Kinase Variants and the Percentage of ALK-Positive Tumor Cells and the Efficacy of Crizotinib in Advanced NSCLCYuan-Yuan Lei, Jin-Ji Yang, Xu-Chao Zhang, et al.
Translational Lung Cancer Research|November 14, 2025
Single-cell RNA profiling reveals an immunosuppressive microenvironment in <i>EGFR</i> double-mutant non-small cell lung cancerJiao Yang, Jun-Wei Su, Hong-Rui Li, et al.
Cancers|January 8, 2023
Longitudinal Plasma Proteomics-Derived Biomarkers Predict Response to MET Inhibitors for MET-Dysregulated NSCLCGuang-Ling Jie, Lun-Xi Peng, Mei-Mei Zheng, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 27, 2011
Relative abundance of EGFR mutations predicts benefit from gefitinib treatment for advanced non-small-cell lung cancerQing Zhou, Xu-Chao Zhang, Zhi-Hong Chen, et al.
European Journal of Cancer (Oxford, England : 1990)|April 21, 2021
Clinical outcomes of non-small cell lung cancer patients with leptomeningeal metastases after immune checkpoint inhibitor treatmentsMei-Mei Zheng, Hai-Yan Tu, Jin-Ji Yang, et al.
Experimental Hematology & Oncology|November 11, 2021
MET amplification identified by next-generation sequencing and its clinical relevance for MET inhibitorsLun-Xi Peng, Guang-Ling Jie, An-Na Li, et al.
Journal of Genetics and Genomics = Yi Chuan Xue Bao|November 12, 2015
Integrative Analyses of Lung Squamous Cell Carcinoma in Ten Chinese Patients with Transcriptome SequencingLu-Lu Yang, Xu-Chao Zhang, Shao-Kun Chuai, et al.
Cancer Immunology, Immunotherapy : CII|December 8, 2017
Characterization of PD-L1 expression in Chinese non-small cell lung cancer patients with PTEN expression as a means for tissue quality screeningXu-Chao Zhang, Xu Cao, Chun Sun, et al.
BMC Cancer|February 26, 2016
Distribution and prognosis of uncommon metastases from non-small cell lung cancerFei-Yu Niu, Qing Zhou, Jin-Ji Yang, et al.
Thoracic Cancer|April 19, 2022
Clinical outcomes of EGFR+/METamp+ vs. EGFR+/METamp- untreated patients with advanced non-small cell lung cancerKai-Cheng Peng, Jun-Wei Su, Zhi Xie, et al.
Pageof 29